Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging

Bravo, Paco E.; Raghu, Ganesh; Rosenthal, David G.; Elman, Shana; Petek, Bradley J.; Soine, Laurie A.; Maki, Jeffrey H.; Branch, Kelley R.; Masri, Sofia Carolina; Patton, Kristen K.; Caldwell, James H.; Krieger, Eric V.

doi:10.1016/j.ijcard.2017.03.033

Cited by 42 publications

(21 citation statements)

References 31 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For CMR, we reviewed the full text of 45 articles and selected 11 (156)(157)(158)(159)(160)(161)(162)(163)(164)(165)(166). For cPET, we reviewed the full text of 34 articles and selected 6 (164)(165)(166)(167)(168)(169). For TTE, we reviewed the full text of 30 articles and selected 2 (148,149).…”

Section: For Patients With Sarcoidosis Whomentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline

Crouser

Maier²,

Wilson

et al. 2020

Am J Respir Crit Care Med

608

507

View full text Add to dashboard Cite

Background: The diagnosis of sarcoidosis is not standardized but is based on three major criteria: a compatible clinical presentation, finding nonnecrotizing granulomatous inflammation in one or more tissue samples, and the exclusion of alternative causes of granulomatous disease. There are no universally accepted measures to determine if each diagnostic criterion has been satisfied; therefore, the diagnosis of sarcoidosis is never fully secure. Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize the best available evidence. The evidence was appraised using the Grading of Recommendations, Assessment, Development, and Evaluation approach and then discussed by a multidisciplinary panel. Recommendations for or against various diagnostic tests were formulated and graded after the expert panel weighed desirable and undesirable consequences, certainty of estimates, feasibility, and acceptability. Results: The clinical presentation, histopathology, and exclusion of alternative diagnoses were summarized. On the basis of the available evidence, the expert committee made 1 strong recommendation for baseline serum calcium testing, 13 conditional recommendations, and 1 best practice statement. All evidence was very low quality. Conclusions: The panel used systematic reviews of the evidence to inform clinical recommendations in favor of or against various diagnostic tests in patients with suspected or known sarcoidosis. The evidence and recommendations should be revisited as new evidence becomes available.

show abstract

Section: For Patients With Sarcoidosis Whomentioning

confidence: 99%

“…Three studies evaluated both CMR and cPET, thereby enabling comparison of the tests within a population (164)(165)(166). In one study, adverse cardiac events were better predicted by CMR (HR, 10.63; 95% CI, 1.4-80.78) than cPET (HR, 2.29; 95% CI, 0.72-7.33) (166).…”

Section: For Patients With Sarcoidosis Whomentioning

confidence: 99%

Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline

Crouser

Maier²,

Wilson

et al. 2020

Am J Respir Crit Care Med

608

507

View full text Add to dashboard Cite

show abstract

“…This was suggested in another study where 56 patients with suspected CS were sequentially evaluated with PET/CT and MRI systems, and retrospectively followed for 2.6 years (IQR 1.2–4.1) for the occurrence of major events. 53 The main findings were that the risk of all-cause death and ventricular arrhythmic events (n = 16/56) was similarly elevated between LGE-positive/FDG-positive (n = 7/20, HR 10.1 [95% CI 1.2–84]) and LGE-positive/FDG-negative (n = 8/16, HR 13.3 [1.7–107]) individuals, in referenced to patients with absent LGE and FDG, whom had the best outcomes (n = 1/20). Of note, FDG-positive/LGE-negative patients were not documented in this study, which was most likely the result of excluding cases showing diffuse and focal on diffuse myocardial FDG uptake from the study.…”

Section: Combined Use Of Cmr and Fdg Petmentioning

confidence: 99%

Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis

Bravo

Singh

Carli

et al. 2019

Journal of Nuclear Cardiology

Self Cite

View full text Add to dashboard Cite

Cardiac sarcoidosis (CS) remains an intriguing infiltrating disorder and one of the most important forms of inflammatory cardiomyopathy. Identification of patients with CS is of extreme importance because they are at higher risk of sudden death, and heart-failure progression. And while it remains a diagnostic conundrum, a great amount of experience has been accumulated over the last decade with the advent of fluorine-18 fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance with late gadolinium enhancement imaging. They have both proven to be advanced imaging techniques that provide important, and often complementary, diagnostic and prognostic information for the management of CS. However, they have also shown to have limitations, and, thus, there is a continued need for developing more specific imaging probes for identifying cardiac inflammation. The aim of the present manuscript is to provide the reader with a better understanding of the histopathology of the disease, how this potentially relates to noninvasive imaging detection, and the best strategies available for the diagnosis and management of patients with CS.

show abstract

“…In terms of prognosis, LGE appears to be more important than 18 F-FDG uptake on PET imaging (49) and can therefore be used in decision making regarding device implantation.…”

Section: Cmrmentioning

confidence: 99%

Advanced Imaging in Cardiac Sarcoidosis

et al. 2019

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) identify high-risk clinical features that necessitate evaluation for cardiac sarcoidosis; (2) understand key histopathologic features of cardiac sarcoidosis and how they relate to different imaging modalities; and (3) recognize the importance of cardiac imaging modalities in the evaluation of patients with suspected or established cardiac sarcoidosis. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through July 2022. Sarcoidosis is a chronic disease of unknown etiology characterized by the presence of noncaseating granulomas. Cardiac involvement in sarcoidosis may lead to adverse outcomes such as advanced heart block, arrhythmias, cardiomyopathy, or death. Cardiac sarcoidosis can occur in patients with established sarcoidosis, or it can be the sole manifestation of the disease. Traditional diagnostic techniques, including echocardiography, have poor sensitivity for diagnosing cardiac sarcoidosis. The accumulating evidence supports the essential role of advanced cardiac imaging modalities such as MRI and PET in diagnosis, risk stratification, and management of patients with cardiac sarcoidosis. The current review highlights important theoretic and practical aspects of using cardiac imaging tools in the evaluation of patients with suspected or established cardiac sarcoidosis.

show abstract

Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging

Cited by 42 publications

References 31 publications

Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline

Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline

Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis

Advanced Imaging in Cardiac Sarcoidosis

Contact Info

Product

Resources

About